{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:07Z","timestamp":1762842187532,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"Shanghai Jiao Tong University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100373","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T22:59:29Z","timestamp":1617922769000},"page":"100373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Ling","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctarc.2021.100373_bib0001","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.ctarc.2021.100373_bib0002","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2021.100373_bib0003","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100373_bib0004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100373_bib0005","unstructured":"http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm376058.htm."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100373_bib0006","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2011030277","article-title":"c-Met and NF-\u03baB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease","volume":"23","author":"Qin","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100373_bib0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.2013.102","article-title":"Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury","volume":"84","author":"Zhou","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.ctarc.2021.100373_bib0008","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202570s006lbl.pdf."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100373_bib0009","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100373_bib0010","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1634\/theoncologist.2014-0216","article-title":"Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment","volume":"19","author":"Klempner","year":"2014","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100373_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1148\/radiology.158.1.3510019","article-title":"The current radiological approach to renal cysts","volume":"158","author":"Bosniak","year":"1986","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100373_bib0012","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/JTO.0000000000000326","article-title":"Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100373_bib0013","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1200\/jco.2011.29.15_suppl.7514","article-title":"Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005","volume":"29","author":"Crin\u00f2","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2021.100373_bib0014","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2021.100373_bib0015","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3390\/ijms19102902","article-title":"Renal injury during long-term crizotinib therapy","volume":"19","author":"Yasuma","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100373_bib0016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radcr.2016.04.010","article-title":"Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report","volume":"11","author":"Chan","year":"2016","journal-title":"Radiol. Case Rep."},{"key":"10.1016\/j.ctarc.2021.100373_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.urology.2019.04.035","article-title":"A complex renal cyst in a patient on crizotinib: case report","volume":"131","author":"Liaw","year":"2019","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100373_bib0018","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiol.2362040218","article-title":"How I do it: evaluating renal masses","volume":"236","author":"Israel","year":"2005","journal-title":"Radiology"},{"issue":"21","key":"10.1016\/j.ctarc.2021.100373_bib0019","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1002\/cncr.27450","article-title":"Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer","volume":"118","author":"Weickhardt","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100373_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000430852","article-title":"Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data","volume":"38","author":"Toyokawa","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ctarc.2021.100373_bib0021","unstructured":"US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s) of ceritinib. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205755Orig1s000ClinPharmR.pdf. Accessed 28 May 2018."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422100071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422100071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:19:48Z","timestamp":1762841988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422100071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"alternative-id":["S246829422100071X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100373","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100373"}}